Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a look at pharma CEO pay; Pfizer’s CEO gives the inside track on COVID vaccine development; GSK elaborates on its restructuring and strategic plans; and Kite talks about its cell therapy plans under Gilead.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 25 June 2021, including: a look at pharma CEO pay; Pfizer Inc.’s CEO gives the inside track on COVID-19 vaccine development; GlaxoSmithKline plc elaborates on its restructuring and strategic plans; and Kite Pharma, Inc. talks about its cell therapy plans under Gilead Sciences, Inc.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration" - Scrip, 22 Jun, 2021.)
(Also see "How Pfizer Crafted Its Own ‘Operation Warp Speed’ For The COVID-19 Vaccine" - Scrip, 24 Jun, 2021.)
(Also see "‘New GSK’ Still Has Some Convincing To Do" - Scrip, 24 Jun, 2021.)
(Also see "GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities" - Scrip, 23 Jun, 2021.)
(Also see "Kite CEO Christi Shaw On How Gilead Plans To Stay On Top In Cell Therapy" - Scrip, 21 Jun, 2021.)